他扎罗汀凝胶治疗寻常型痤疮的临床疗效和安全性评价

目的观察他扎罗汀凝胶治疗寻常型痤疮的临床疗效和安全性。方法寻常型痤疮患者60例，随机分为治疗组30例，外用0．1％他扎罗汀凝胶每晚1次，连用8周；对照组30例，外用迪维霜每晚1次，连用8周，停药后观察疗效。结果治疗组痊愈11例，显效13例，总有效率80％；对照组痊愈6例，显效10例，总有效率53．3％。两组结果经统计学处理，x^2=4．8，P〈0．05，差异有显著性。结论他扎罗汀凝胶治疗寻常型痤疮是一种安全、有效的药物。     

他扎罗汀凝胶治疗寻常性痤疮的有效性

目的观察他扎罗汀凝胶治疗寻常型痤疮的临床疗效和安全性。方法寻常型痤疮患者46例,随机分为治疗组23例,外用0.1%他扎罗汀凝胶每晚1次,连用8周;对照组23例,外用迪维霜每1晚1次,连用8周,停药后观察疗效。结果治疗组痊愈9例,显效11例,总有效率80%;对照组痊愈6例,显效9例,总有效率60%。结论他扎罗汀凝胶治疗寻常型痤疮是一种安全、有效的药物。     

阿达帕林凝胶治疗寻找座疮临床观察

目的：观察0．1％阿达帕林凝胶治疗寻常痤疮的临床疗效和安全性，方法：160例寻常痤疮患者，分别给予外涂0．1％阿达帕林凝胶（80例）及0．025％全反维A酸凝胶（80例），根据治疗前后炎性损害和非炎性损害总数减少的百分率评价疗效。结果：两组痊愈率，显效率，有效率均无统计学差异，阿达帕林组不良反应率明显低于全反维A酸组，结论：0．1％阿达帕林是一种局部治疗寻常痤疮的有效的安全的药物。     

他扎罗汀凝胶联合美满霉素治疗囊肿性痤疮50例

目的观察他扎罗汀凝胶联合美满霉素治疗囊肿性痤疮的临床疗效。方法治疗组口服美满霉素50mg，外用他扎罗汀凝胶，均2次／d；对照组口服琥乙红霉素0．25g（3次／d），外用0．05％维甲酸霜（2次／d）。两组疗程均为8周。结果治疗组有效率达96．0％，对照组有效率为84．0％，两组相比差异无显著性（P〈0．05）。结论他扎罗汀凝胶联合美满霉素治疗囊肿性痤疮安全、有效。     

他扎罗汀凝胶联合益肤清乳膏治疗寻常性斑块型银屑病30例

目的探讨他扎罗汀凝胶联合益肤清乳膏治疗寻常性斑块型银屑病的临床疗效。方法将60例寻常性斑块型银屑病患者随机分为两组,各30例,治疗组外用他扎罗汀凝胶与益肤清乳膏,对照组仅单纯外用益肤清乳膏,两组疗程均为12周。结果治疗组总有效率为86.67%,明显高于对照组的60.00%(P<0.05);不良反应发生率治疗组为10.00%,对照组为6.67%。结论他扎罗汀凝胶联合益肤清乳膏治疗寻常性斑块型银屑病疗效好、安全性高。     

润燥止痒胶囊联合培氟沙星乳膏、阿达帕林凝胶治疗寻常型痤疮疗效观察

目的：观察润燥止痒胶囊联合培氟沙星乳膏、阿达帕林凝胶治疗寻常型痤疮的临床疗效。方法将86例痤疮患者随机分为两组,对照组43例应用培氟沙星乳膏及阿达帕林凝胶外用治疗;治疗组加用润燥止痒胶囊口服。疗程均为4周。结果治疗组有效率为81.39%,对照组有效率为58.13%,治疗组疗效优于对照组,两组疗效比较差异有统计学意义（P〈0.05）。结论润燥止痒胶囊联合培氟沙星乳膏及阿达帕林凝胶治疗寻常型痤疮疗效肯定,无不良反应。     

刺山柑乳膏治疗银屑病的临床观察

目的探讨刺山柑乳膏治疗寻常型银屑病的疗效。方法80例银屑病患者按随机数字表随机分为观察组（37例）和对照组（43例）。2组均口服阿维A胶囊10mg,2次／d,观察组患者外用刺山柑乳膏2次／d,对照组患者外用他扎罗汀凝胶2次／d,共8周。记录治疗效果及不良反应。结果治疗8周后,观察组患者皮损有效率为94．6％（35／37）,对照组93．0％（40／43）,2组比较差异无统计学意义（P〉0．05）。观察组不良反应发生率低于对照组[18．9％（7／37）比46．5％（20／43）,P〈0．05]。结论刺山柑乳膏治疗寻常型银屑病安全有效。     

金花消痤丸联合0.05%他扎罗汀乳膏治疗寻常性痤疮的疗效观察

目的:观察金花消痤丸联合0.05%他扎罗汀乳膏对寻常性痤疮的疗效。方法:将64例寻常性痤疮患者根据就诊次序随机分为治疗组和对照组各32例。治疗组外用0.05%他扎罗汀乳膏,每晚1次,同时口服金花消痤丸,每次4g,tid;对照组外用氯霉素甲硝唑搽剂,tid。2组均连续用药6周。对治疗前及治疗后的疗效进行评定,采用SPSS13.0统计软件分析结果。结果:治疗组与对照组有效率分别为93.8%、65.6%,2组比较有显著性差异(χ2=7.169,P<0.01)。结论:金花消痤丸联合0.05%他扎罗汀乳膏治疗寻常性痤疮疗效显著,未见明显不良反应。     

阿达帕林凝胶治疗寻常型痤疮98例

目的：评价阿达帕林凝胶治疗寻常型痤疮的疗效与安全性。方法：寻常型痤疮患者随机分为两组，治疗组98例，每晚睡前外用0.1%阿达帕林凝胶均匀地涂在皮损处，qd。对照组56例，每晚睡前外用5%水硫洗剂涂皮损处1次，白天外用5%硫磺乳膏涂皮损处1次。均3个月为1个疗程。每隔1～2周复诊1次，记录皮疹变化及局部刺激反应。结果：治疗组总有效率78.6%，对照组总有效率50.0%，两组差异有显著性(P＜0.05)。其中治疗组中7例有暂时性红斑，干燥，脱屑等全身反应。结论：阿达帕林凝胶治疗寻常痤疮使用方便，疗效明显。     

咪喹莫特联合他扎罗汀治疗扁平疣的临床观察

目的:探讨5%咪喹莫特乳膏联合0.05%他扎罗汀凝胶治疗扁平疣的临床疗效和安全性。方法:以随机分配原则将扁平疣患者分为两组,联合组32例,接受5%咪喹莫特乳膏、0.05%他扎罗汀凝胶联合治疗;对照组3 l例接受单纯0.05%他扎罗汀凝胶治疗,疗程8周。根据观察疣体数目变化,评判疗效。结果:同时使用5%咪喹莫特乳膏和0.05%他扎罗汀凝胶联合组有效率明显高于单纯使用的0.05%他扎罗汀凝胶的对照组(P<0.05)。结论:5%咪喹莫特乳膏和0.05%他扎罗汀凝胶联合治疗扁平疣安全有效,且疗效优于单纯应用0.05%他扎罗汀凝胶。     

异维A酸红霉素凝胶治疗痤疮的疗效观察

目的:观察异维A酸红霉素凝胶治疗轻、中度寻常痤疮的疗效。方法:将50例轻、中度面部寻常痤疮患者按面部左右侧分为2组,治疗组:左侧面部外用异维A酸红霉素凝胶,每晚1次;对照组:右侧面部外用维胺脂维E乳膏,每晚1次。比较第6周和第8周2组疗效。结果:治疗第6周时,治疗组与对照组的有效率分别为70%、42%(P<0.05);治疗第8周时,治疗组与对照组的有效率分别为82%、76%(P>0.05);对于炎性皮损,在治疗第6、8周时,2组疗效差异有统计学意义(P<0.05)。结论:异维A酸红霉素凝胶治疗轻、中度痤疮疗效确切,起效较维胺脂维E乳膏快。当皮损以炎性丘疹为主时,异维A酸红霉素凝胶疗效优于维胺脂维E乳膏。     

Adapalene: a review of its use in the treatment of acne vulgaris

Adapalene (Differin) is a retinoid agent indicated for the topical treatment of acne vulgaris. In clinical trials, 0.1% adapalene gel has proved to be effective in this indication and was as effective as 0.025% tretinoin gel, 0.1% tretinoin microsphere gel, 0.05% tretinoin cream and 0.1% tazarotene gel once every two days; however, the drug was less effective than once-daily 0.1% tazarotene gel. It can be used alone in mild acne or in combination with antimicrobials in inflammatory acne and has proved efficacious as maintenance treatment. Adapalene has a rapid onset of action and a particularly favourable tolerability profile compared with other retinoids. These attributes can potentially promote patient compliance, an important factor in treatment success. Adapalene is, therefore, assured of a role in the first-line treatment of acne vulgaris.     

他扎罗汀乳膏治疗痤疮的临床疗效观察

目的:为痤疮患者提供更好的治疗方案。方法:122例痤疮患者按随机单盲对照原则分为他扎罗汀组(42例)、水氯酊组(38例)和联合治疗组(42例),连续外用8周后观察疗效。结果:3组皮损数均随治疗时间的延长而逐渐减少,与治疗前比较,治疗8周后皮损总分3组差异均有统计学意义(P<0.05或P<0.01)。治疗8周后有效率,他扎罗汀组与水氯酊组比较差异有统计学意义(χ2=17.629,P<0.05);联合治疗组与水氯酊组比较差异也有统计学意义(χ2=15.532,P<0.05);他扎罗汀组与联合治疗组比较差异无统计学意义(χ2=10.130,P>0.05)。结论:对于非炎症性痤疮可单用他扎罗汀治疗;对脓疱型患者水氯酊效果优于他扎罗汀,考虑与氯霉素的抗菌作用有关;而对于炎症性痤疮可选用他扎罗汀加0.5%水氯酊外用。     

异维A酸红霉素凝胶治疗寻常痤疮的多中心随机平行对照临床试验

目的:评价异维A酸红霉素凝胶治疗轻、中度寻常痤疮的疗效和安全性。方法:采用多中心随机、盲法、阳性药平行对照试验设计。试验组予异维A酸红霉素凝胶,对照组予维A酸乳膏。均为每晚一次,涂抹在全部患处,疗程为8 wk,观察疗效及不良反应。结果:共入组240例病人,进入疗效分析226例,其中试验组111例,对照组115例。治疗后,试验组与对照组综合疗效有效率分别为87.4% (97/111)和81.7%(70/115),2组综合疗效无显著差异(P>0.05);不良反应发生率分别为10.2%和7.6%(P>0.05)。结论:异维A酸红霉素凝胶治疗轻、中度寻常痤疮安全有效。     

他扎罗汀凝胶与卡泊三醇软膏治疗斑块型银屑病的比较

目的 :观察他扎罗汀凝胶治疗斑块型银屑病的疗效与安全性 ,并与卡泊三醇软膏比较。方法 :71例斑块型银屑病病人分为 2组 ,他扎罗汀组 36例 ,每晚外涂 1次 ;卡泊三醇组 35例 ,早、晚各外涂1次 ,2组疗程均为 12wk。结果 :2组的总有效率分别为 83%和 79% ,差异无显著意义 (P >0 .0 5 )。结论 :他扎罗汀凝胶治疗斑块型银屑病安全有效 ,与卡泊三醇相仿     

Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial

Topical retinoids offer highly effective treatment for both inflammatory and non-inflammatory acne, with tazarotene demonstrating greater efficacy than other topical retinoids. A multicenter, double-blind, randomized, parallel-group trial has been performed to evaluate whether the adjunctive use of clindamycin/benzoyl peroxide could enhance the efficacy of tazarotene still further. Patients with moderate to severe inflammatory acne applied tazarotene 0.1% cream each evening and were randomly assigned to morning applications of vehicle gel or a ready-to-dispense formulation of clindamycin 1%/benzoyl peroxide 5 % gel containing 2 emollients. Tazarotene/clindamycin/benzoyl peroxide achieved a significantly greater reduction in comedo count than tazarotene monotherapy and, among patients with a baseline papule plus pustule count of > or =25 (the median value), a significantly greater reduction in inflammatory lesion count. The combination therapy was also at least as well-tolerated as tazarotene monotherapy. The adjunctive use of clindamycin/benzoyl peroxide gel with tazarotene cream promotes greater efficacy and may also enhance tolerability. Any improvements in tolerability could be due to the emollients in the clindamycin/benzoyl peroxide gel formulation.     

Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin

OBJECTIVE: To evaluate the safety and pharmacokinetics of tazarotene cream 0.1% under standard (face only) or exaggerated (15% body surface area, including the face) application conditions after a single dose and after repeat topical applications once daily to patients with acne vulgaris or photodamaged skin. METHODS: Two separate, randomised, single-centre, nonblinded, parallel-group pharmacokinetic studies were conducted. In one study, tazarotene cream 0.1% was applied either to the face of eight female patients with moderate acne or to 15% body surface area of ten female patients with severe acne. In the other study, tazarotene cream 0.1% was applied either to the face (six females, two males) or to 15% body surface area (8 females, 8 males) of patients with photodamaged skin. In both studies, tazarotene cream 0.1% was applied once daily (except on days 1 and 2) for 30 days. Blood was drawn for measurement of plasma concentrations of tazarotenic acid at defined time intervals after application of the cream. Plasma tazarotenic acid concentrations were determined by a validated gas chromatography-tandem mass spectrometry method with a lower limit of quantification of 0.005 microg/L. RESULTS: At exaggerated application rates in patients with acne vulgaris, the maximum average peak concentration (C(max)) and 24-hour area under the concentration-time curve (AUC) values of tazarotenic acid were (mean +/- SD) 1.20 +/- 0.41 microg/L (n = 10) and 17.0 +/- 6.1 microg. h/L (n = 10), respectively, and occurred on day 15. The single highest C(max) was 1.91 microg/L. At standard application rates in patients with acne vulgaris, the maximum average C(max) and AUC values of tazarotenic acid were 0.10 +/- 0.06 microg/L (n = 8) and 1.54 +/- 1.01 microg. h/L (n = 8), respectively, and occurred on day 15. At exaggerated application rates in patients with photodamaged skin, the maximum average C(max) and AUC values of tazarotenic acid were (mean +/- SD) 1.75 +/- 0.53 microg/L (n = 16) and 23.8 +/- 7.0 microg. h/L (n = 16), respectively, and occurred on day 22. The single highest C(max) was 3.43 microg/L on day 29. At standard application rates in patients with photodamaged skin, the maximum average C(max) and AUC values of tazarotenic acid were 0.236 +/- 0.255 microg/L (n = 8) and 2.44 +/- 1.38 microg. h/L (n = 8), respectively, and occurred on day 15. Gender had no influence on the systemic exposure of tazarotenic acid. The most common treatment-related adverse events were signs and symptoms of local irritation, of mild or moderate severity. CONCLUSIONS: The pharmacokinetics of tazarotene cream 0.1% in patients with acne vulgaris or photodamaged skin are similar. The maximum average plasma concentrations of tazarotenic acid after topical application of tazarotene cream 0.1% to the face were less than 0.25 microg/L. The maximum average plasma concentrations of tazarotenic acid following application to an exaggerated body surface area (15%) were less than 1.8 microg/L.     

五味消毒饮内服外敷治疗寻常性痤疮35例临床观察

目的:观察五味消毒饮加减内服外敷治疗寻常性痤疮临床疗效。方法:60例痤疮患者随机分为两组,治疗组35例,采用五味消毒饮加减内服外敷联合治疗方法。对照组25例,口服甲硝唑片,睡前外用维A酸乳膏。结果:治疗组痊愈率51.4%,总有效率97.1%;对照组痊愈率24.0%,总有效率80.0%。两组痊愈率与总有效率比较,差异均有显著性(P<0.05)。结论:五味消毒饮加减内服外敷法治疗寻常性痤疮有显著疗效,安全性好。     

阿达帕林凝胶治疗寻常痤疮临床观察

目的 :观察 0 1%阿达帕林凝胶治疗寻常痤疮的临床疗效和安全性。方法 :16 0例寻常痤疮患者 ,分别给予外涂 0 1%阿达帕林凝胶 (80例 )及 0 0 2 5 %全反维A酸凝胶 (80例 )。根据治疗前后炎性损害和非炎性损害总数减少的百分率评价疗效。结果 :两组痊愈率、显效率、有效率均无统计学差异 ,阿达帕林组不良反应率明显低于全反维A酸组。结论 :0 1%阿达帕林是一种局部治疗寻常痤疮的有效的安全的药物     

新癀片联合阿奇霉素与0.1%阿达帕林凝胶治疗寻常型痤疮的疗效观察

目的:观察新癀片联合阿奇霉素、0.1%阿达帕林凝胶治疗寻常型痤疮的疗效。方法:将216例Ⅰ、Ⅱ度寻常型痤疮患者根据就诊顺序随机分为治疗组和对照组各108例。治疗组应用新癀片、阿奇霉素口服加外用0.1%阿达帕林凝胶进行治疗;对照组应用红霉素肠溶片口服加外用复方硫磺洗剂。疗程满6周后观察2组疗效。结果:治疗组总有效率为97.2%,对照组总有效率为41.6%,2组比较有显著性差异(P<0.01)。在6周的临床试验中,治疗组的不良反应发生率明显低于对照组(P<0.05)。结论:新癀片联合阿奇霉素、0.1%阿达帕林凝胶治疗Ⅰ、Ⅱ度寻常型痤疮可明显缓解病情、缩短病程,且不良反应轻微。